Recombinant activated factor VII (rFVIIa, eptacog alfa, NovoSeven ® , NovoNordisk, Copenhagen, Denmark) appears to be an effective agent for the correction of a wide range of coagulopathies 1 . It has been available commercially in Australia since 1998, although at present it is approved by the Therapeutic Goods Administration (TGA) only for use in patients with factor VIII or IX deficiency with inhibitors 2 . Its use for patients with life-threatening coagulopathic bleeding is increasing, despite being "off-label" for this indication. This is due mainly to the large number of case reports and series demonstrating improved coagulation after its use [3] [4] [5] [6] [7] [8] [9] [10] .
In the current issue, Gowers and Parr report a retrospective study of its use in nine patients with "refractory coagulopathy" unresponsive to maximal conventional therapy, and "in imminent danger of death" 11 . They found an improvement in coagulation parameters in all nine patients, with reduced requirements for coagulation products, and survival to discharge in seven out of the nine. None of the patients developed thrombotic complications attributable to rFVIIa. This report adds to the growing body of evidence, albeit relatively anecdotal (level 4), of the efficacy and safety of rFVIIa in patients with severe coagulopathic bleeding.
As it happens, relatively anecdotal evidence may be the best that we are likely to obtain in patients "in imminent danger of death". If a severe coagulopathy persists despite maximal conventional therapy, and bleeding cannot be arrested surgically, it would now be unethical to withhold rFVIIa. This is because rFVIIa has often been associated with improved outcome in case reports, and thrombotic complications have been rare. This means that it is unlikely there will be randomised controlled clinical trials to guide the use of rFVIIa in these situations. Moreover, when used for refractory coagulopathies causing lifethreatening bleeding, the patient acts in many ways as their own control. They demonstrate that they have 'failed' conventional therapy and would not be expected to survive using further conventional therapy alone. Any improvement in coagulation or bleeding can then be presumed to be due to the effect of rFVIIa, although this can never be proven.
This begs the question about what should be considered "maximal conventional therapy". This cannot be defined easily, but will inevitably involve massive transfusion of blood products, other pharmacological interventions to promote coagulation, and exhaustive attempts to control the blood loss surgically 12 . Gowers and Parr suggest that each institution should develop their own protocols and guidelines for the use of rFVIIa in this situation. They indicate sensibly that this is best achieved by a multidisciplinary approach, involving haematologists, surgeons, and anaesthetists, as well as blood transfusion services.
One of the reasons often cited for controlling the use of rFVIIa is its high cost. While its cost is indeed high, the main factors currently limiting its use are concerns about its safety (given its theoretical prothrombotic effect) 13 , and the limited TGA approval. While safety concerns and obtaining informed consent may be less of a concern in a patient otherwise facing almost certain death, they are extremely important when using an "off-label" drug in a patient expected to survive. For this reason, the current role of rFVIIa for severe coagulopathy and bleeding appears to be limited to life-threatening situations only. Recombinant activated factor VII may also be particularly helpful for patients who refuse blood transfusion (e.g. Jehovah's Witnesses), and for those for whom no blood products are available.
At present, there are several prospective multicentre randomised controlled clinical trials being conducted worldwide to examine the efficacy and safety of rFVIIa in many types of coagulopathy and bleeding, including trauma, transplantation, cardiac surgery, and intracerebral haemorrhage 14 . These trials will help define the risk-benefit and cost-benefit profiles, and optimal dosing of rFVIIa. However, they all involve administering rFVIIa earlier in each event, and they examine total blood product use and blood loss, as well as complication rates, safety and survival as outcome measures. In addition, they all require patient informed consent, not only for participation in a clinical trial, but also for the use of an "off-label" drug. This is very different to the use of rFVIIa during established life-threatening bleeding. For life-threatening coagulopathic bleeding, we are reliant, at least for the present, on the type of reports provided by Gowers 
